Role and rationale of gene therapy and other novel therapies in the management of NMIBC

Expert Review of Anticancer Therapy

Volumn 9, Issue 12, 2009, Pages 1777-1782

  Rial, Carlos Lojo ^a   Wilby, Daniel ^b   Sooriakumaran, Prasanna ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Gene therapy; Monoclonal antibodies; Non muscle invasive bladder cancer; Novel intravesical therapy; Viruses

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BCG VACCINE; BEVACIZUMAB; CD40 LIGAND; CETUXIMAB; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DOXORUBICIN; ERLOTINIB; GLYCOSAMINOGLYCAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; LIPOSOME; MITOMYCIN C; MONOCLONAL ANTIBODY; PARVOVIRUS VECTOR; PLASMID VECTOR; PROTEIN P53; SMALL INTERFERING RNA; VIRUS DNA; VIRUS VECTOR;

APOPTOSIS; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL TRIAL; CYSTECTOMY; DISEASE ACTIVITY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROGNOSIS; REVIEW; SURVIVAL RATE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GENE THERAPY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ONCOLYTIC VIROTHERAPY; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 73349090876     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.106     Document Type: Review

References (46)

1. Schmidbauer J, Lindenau G. Follow up of non muscle invasive transitional cell carcinoma of the bladder: how and how often? Curr. Opin. Urol. 18, 504-507 (2008).
2. Stief CG. Editorial. Eur. Urol. 7, 509 (2008).
3. Scelo G, Brennan P. The epidemiology of bladder and kidney cancer. Nat. Clin. Pract. Urol. 4, 205-217 (2007).
4. Colombel M, Soloway H, Akaza A et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur. Urol. 7(Suppl.), 618-626 (2007).
5. Dalbagni G. The management of superficial bladder cancer. Nat. Clin. Pract. Urol. 4, 254-260 (2007)
6. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JLS. Intravesical treatments of bladder cancer: review. Pharm. Res. 25, 1500-1510 (2008).
7. Liang FX, Riedel I, Deng FM et al. Organization of uroplakin subunits: transmembrane topology, pair formation and plaque composition. Biochem. J. 355, 13-18 (2001).
8. Chester JD, Kennedy W, Hall GD et al. Adenovirus mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo. Gene Ther. 10, 172-179 (2003).
9. Bochner BH. Gene therapy in bladder cancer. Curr. Opin. Urol. 18, 519-523 (2008). Describes some of the new advances in gene delivery, the role of viral and nonviral modes of gene therapy, and focuses on the importance of Coxsackie adenoviral receptors. It also discusses gene-directed enzyme prodrug therapy, immunomodulation and interferon therapy.
10. Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vector. Cancer Res. 54, 3325-3328 (1994).
11. Kikuchi E, Menendez S, Ozu C et al. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Clin. Cancer Res. 13, 4511-4518 (2007).
12. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331, 1259-1264 (1994).
13. Kelly JD, Williamson KE, Irvine AE et al. Apoptosis and its clinical significance for bladder cancer therapy. Br. J. Urol. 83, 1-10 (1999).
14. Kuball J, Wen SF, Leissner J et al. Successful adenovirus mediated type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol. 20, 957-965 (2003).
15. Pagliaro LC, Keyhani A, Williams D et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a Phase I study of p53 gene therapy. J. Clin. Oncol. 21, 2247-2253 (2003).
16. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J. Urol. 173, 604-609 (2005). This study used vaccinia virus (VV) to deliver gene therapy in a mouse model. The authors found that cell death was greater when p53 was added to the VV with decreased tumor survival.
17. Kassouf W, Kamat AM. Current state of immunotherapy for bladder cancer. Expert Rev. Anticancer Ther. 4(6), 1037-1046 (2004).
18. Mitropoulos DN. Novel insights into the mechanism of action of intravesical immunomodulators. In Vivo 19, 611-621 (2005).
19. Tao Z, Connor RJ, Ashoori F et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigations. Cancer Gene Ther. 13, 125-130 (2006).
20. Nagabhushan TL, Maneval DC, Benedict WF et al. Enhancement of intravesical delivery with Syn3 Potentiates interferon-α2b gene therapy for superficial bladder cancer. Cytokines Growth Factor Rev. 18, 389-394 (2007). This is an excellent review on the use of Syn3 in a bladder cancer animal model. Syn3 appears to increase the concentration of IFN-α within the bladder with greater tumoricidal effects compared with IFN therapy alone.
21. Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF. Adenoviral-mediated interferon α overcomes resistance to the interferon protein in various cancer types and has marker bystander effects. Cancer Gene Ther. 14, 241-250 (2007).
22. Ahirwar D, Mandhani A, Mittal RD. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Arch. Med. Res. 40, 97-102 (2009).
23. Dranoff G, Jaffee E, Lazenby A. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific and long lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993).
24. Ramesh N, Ge Y, Ennist DL et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12, 305-313 (2006).
25. Nogawa M, Yuasa T, Kimura S et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. Clin. Invest. 115, 978-985 (2005). In this study PLK-1 was found to be a poor prognostic factor in bladder cancer. PLK-1 inhibition was shown by the authors to block tumor cell proliferation and induce apoptosis.
26. Gravas S, Bosinakou I, Kehayas P, Giannopoulos A. Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol. Int. 73, 173-177 (2004).
27. Wood CG, Perrotte P, Inoue K, Eve B, Dinney CP. Expression of basic fibroblast growth factor (bFGF) mediates the tumorigenic phenotype in human transitional cell carcinoma of the bladder. J. Urol. 159, 1089 (1998).
28. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus medicated antisense basic FGF. Clin. Cancer Res. 6, 4422-4431 (2000).
29. Kikuchi E, Menendez S, Ozu C et al. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther. 14, 279-286 (2007).
30. Zhang Z, Shirakawa T, Hinata N. Combination with CD5-FC gene therapy enhances killing of human bladder cancer cells by radiation. J. Gene Med. 5, 860-867 (2003).
31. Shieh GS, Shiau AL, Yo YT. Low dose etoposide enhances telomerase dependent adenovirus mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res. 66, 9957-9966 (2006).
32. Hou JQ, He J, Wang XL, Wen DG, Chen ZX. Effects of small interfering RNA targeting surviving gene on biological behaviour of bladder cancer. Chin. Med. 119, 1734-1739 (2006).
33. Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 66, 461-466 (2005). The authors investigated the liposomal delivery of IL-12 in bladder cancer and showed that mice with bladder cancer that received higher doses of IL-12 survived longer compared with mice with bladder cancer that did not receive IL-12.
34. Wu Q, Mahendran R, Esuvaranathan K. Nonviral cytokine gene therapy on an orthotopic bladder cancer model. Clin. Cancer Res. 9, 4522-4528 (2003).
35. Kunze D, Wuttig D, Fuessel S et al. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res. 28, 2259-2263 (2008).
36. Kunze D, Wuttig D, Kausch I et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int. J. Oncol. 32, 1049-1056 (2008).
37. Ninalga C, Loskog A, Klevenfeldt M, Essand M, Totterman TH. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumours and evokes protective immunity in murine bladder cancer. J. Immunother. 28, 20-27 (2005).
38. Reither FK, Volpert OV, Jimenez B. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int. J. Cancer 98, 682-689 (2002).
39. Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long term outcome related to EGFR status in bladder cancer. J. Urol. 153, 919-925 (1995).
40. Jimenez RE, Hussain M, Bianco FJ. Her-2/neu overexpression in muscle invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7, 2440-2447 (2001).
41. Kruger S, Weitsch G, Buttner H. HER2 overexpression in muscle invasive urothelial carcinoma of the bladder: prognostic implications. Int. J. Cancer 102, 514-518 (2002).
42. Shepherd FA, Rodrigues-Pereira J, Ciuleanu T. Erlotinib in previously treated non-small cell lung cancer N. Engl. J. Med. 351, 337-345 (2004).
43. Cunningham D, Humbler Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
44. Bonner JA, Harari PM, Giralt J. Radiotherapy plus cetuximab for squamous cell carcinoma of head and neck. N. Engl. J. Med. 354, 567-578 (2006).
45. Black PC, Agarwal PK, Dinney CPN. Targeted therapies in bladder cancer: an update. Urol. Oncol. 25, 433-438 (2007). Considers growth factors as a possible therapeutic target in bladder cancer. It discusses EGF receptor, HER, PDGF receptor-b, FGF receptor 3 and VEGF, and is a useful review of the subject.
46. Kawano H, Komaba S, Yamasaki T et al. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin. Cancer Chemther. Pharmacol. 61, 973-978 (2008).